# Epigeneres Biotech Private

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epigeneres-biotech-private

- Industry: Biotechnology
- Headquarters: Mumbai, India
- Total disclosed funding: $6M
- Latest round: Series B (Dec 9, 2021)
- Investors on record: 5

## About

Founded in 2012 and based in Mumbai, India, Epigeneres Biotech Private Limited operates as a biotechnology company that discovers, develops, manufactures, and commercializes molecular medicines and nutrigenomic formulations in treating cancer and aging diseases. In 2021, the company announced its early-detection cancer test, which was developed with RNA bio-markers technology, which can recognize cancer in stage zero. In December 2021, Epigeneres Biotech Private Limited raised INR 454.16 million in series B funding co-led by new investors Kotak Investment Advisors, LetsVenture, and an individual investor, with participation from other new investors East River Ventures, Nandita Advisors, and One Decacorn. Other individual investors also participated in the round.

The company operates as a medical developer focusing on the cancer testing sector. It reached collaboration with a Singapore-based lab, Tzar Labs, in 2021. There are three most recognizable cancer detection solutions developed by the company -- imminent cancer early-stage test, the prognosis for cancer, and blood test for RNA mutation analysis for organs.

The company will utilize the fund raised in 2021 to develop an AI-powered medical development platform.

## Funding rounds

- Series B, Dec 9, 2021, $6M — Kotak Alternate Asset Managers, East River Ventures, LVX, One Decacorn, Nandita Advisors

## Investors

- Kotak Alternate Asset Managers (https://capitalatlas.ai/funds/kotak-alternate-asset-managers) — Series B
- East River Ventures — Series B
- LVX (https://capitalatlas.ai/funds/lvx) — Series B
- One Decacorn — Series B
- Nandita Advisors — Series B